The number of U.S. retail opioid prescriptions fell by 10.2% in 2017, including a 16.1% decline in high-dose prescriptions, according to a report released today by the IQVIA Institute for Human Data Science. The Centers for Disease Control and Prevention defines high-dose prescriptions as 90 morphine milligram equivalents or more per day. Total MME volume fell by 12%, or 23.3 billion, the largest annual drop in more than 25 years, according to the report. New opioid therapy starts fell 7.8%, while treatment starts for medication-assisted therapies nearly doubled to 82,000 prescriptions per month. The report also includes many other findings about drug spending, including that patients spent $57.8 billion in 2017 in out-of-pocket costs for medicines, including copays, coinsurance, payments during deductible phases of their insurance, or due to lack of insurance coverage.

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…